Millennium Management
VRDN icon

Millennium Management’s Viridian Therapeutics VRDN Stock Holding History

Millennium Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-105,500
Closed -$2.51M – 6616
2023
Q2 		$2.51M Buy
+105,500
New +$2.71M ﹤0.01% 3278
2023
Q1 		– Sell
-90,400
Closed -$2.64M – 6902
2022
Q4 		$2.64M Buy
+90,400
New +$2.08M ﹤0.01% 3329

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Millennium Management's VRDN Position: Q1 2026 in Review

Millennium Management reduced its Viridian Therapeutics (VRDN) stake by 69% in Q1 2026, selling an estimated $9.49M and leaving 140,595 shares worth $2.75M. The position accounts for ﹤0.01% of the portfolio, ranked #3554.

Millennium Management first reported a position in VRDN in Q1 2017 and has held it in 30 quarters since. The position peaked at $31.8M in Q2 2023. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Millennium Management held 140,595 shares of Viridian Therapeutics worth $2.75M as of Q1 2026.
  • Millennium Management sold 319,530 Viridian Therapeutics shares in Q1 2026, an estimated $9.49M.
  • Viridian Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3554 holding.
  • Millennium Management first reported a position in Viridian Therapeutics in Q1 2017 and has held it in 30 quarters since.
  • Millennium Management's Viridian Therapeutics position peaked at $31.8M in Q2 2023.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.